Previous 10 | Next 10 |
The Breast Cancer Index Test Is the First Biomarker to Predict Treatment Benefit in the SOFT Trial Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients wit...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Global Leader in Women’s Health Recognized with Three IMV ServiceTrak™ Awards for Mammography During RSNA 2022 Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, swept the 2022 IMV ServiceTrak™...
New Affirm® Contrast Biopsy Technology Included in the Screening, Diagnosis, Treatment and Monitoring Solutions on Display Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108 th Scientific Assem...
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 5 th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 2:40 p.m. Eastern Time. The fire-side chat presentation will be webcast live and may be accessed through a...
Summary Hologic exceeded expectations again on the back of stronger COVID-19 testing, but underlying diagnostics revenue was also strong. The pandemic greatly accelerated the adoption curve of the Panther diagnostics system, and it will be harder now for new systems to break into ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: What Moved Markets
3Dimensions System Earns Distinction for Meeting or Exceeding Rigorous European Image Quality and Dose Standards Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that its 3Dimensions™ mammography system was awarded EUREF Type...
Hologic ( NASDAQ: HOLX ) on Wednesday said it had got a $19M contract from the Biomedical Advanced Research and Development Authority (BARDA) to support research and development efforts. The funding will "help to bring Hologic’s Panther Fusion SARS-CoV-2/Flu A/...
Agency Awards $19 Million Contract to Fund Research and Development Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to support research and development effort...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...